Indole-3-carbinol induces cMYC and IAP-family downmodulation and promotes apoptosis of Epstein-Barr virus (EBV)-positive but not of EBV-negative Burkitt's lymphoma cell lines by Pérez-Chacón, Gema et al.
  1
Indole-3-carbinol induces cMYC and IAP-family 
downmodulation and promotes apoptosis of Epstein-Barr 
virus (EBV)-positive but not of EBV-negative Burkitt’s 
lymphoma cell lines 
 
Gema Perez-Chacon1, Cristobal de los Rios2,3 and Juan M. Zapata1 
1Instituto de Investigaciones Biomedicas “Alberto Sols”, CSIC/UAM, 2 
Instituto Teofilo Hernando and 3 Departamento de Farmacologia y Terapeutica, 
Facultad de Medicina, UAM, 28029 Madrid, Spain  
 
Running title: I3C induces apoptosis in EBV-positive BL 
 
Corresponding authors: Juan M. Zapata (jmzapata@iib.uam.es) and Gema Perez-Chacon 
(gpchacon@iib.uam.es). Instituto de Investigaciones Biomedicas “Alberto Sols”, 
CSIC/UAM, Madrid 28029, Spain. Phone 34-914977032; Fax 34-915854401 
 
 
ABBREVIATIONS 
ATM, ataxia telangiectasia mutated; ATR, ataxia telangiectasia and Rad3-related; BCL, B 
cell lymphoma; BIR, baculovirus IAP repeat; BL, Burkitt’s lymphoma; CFLAR, CASP8 
and FADD-like apoptosis regulator; cFLIP, Fas-associated death domain protein-like 
interleukin-1-converting enzyme inhibitory protein; cIAP, cellular inhibitor of apoptosis; 
DIM, 3,3´-diindolylmethane; EBV, Epstein-Barr virus; EBNA, Epstein-Barr virus nuclear 
antigen; I3C, indole-3-carbinol; LCL, lymphoblastoid cell line; LMP, Epstein-Barr virus 
latent membrane protein; NOD, non-obese diabetic; PARP, poly(ADP-ribose) polymerase; 
SCID, severe combined immunodeficiency; TCL,  T cell lymphoma; XIAP, X-linked 
inhibitor of apoptosis.
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ABSTRACT 
 
Indole-3-carbinol (I3C) is a natural product found in broadly consumed plants of the 
Brassica genus, such as broccoli, cabbage, and cauliflower, which exhibits anti-tumor 
effects through poorly defined mechanisms. I3C can be orally administered and clinical 
trials have demonstrated that I3C and derivatives are safe in humans. In this study we show 
that I3C efficiently induces apoptosis in cell lines derived from EBV-positive Burkitt’s 
lymphomas (virus latency I/II), while it does not have any cytotoxic activity against EBV-
negative Burkitt’s lymphomas and immortalized EBV-infected lymphoblastoid cell lines 
(virus latency III). The effect of I3C in EBV-positive Burkitt’s lymphoma is very specific, 
since only I3C and its C6-methylated derivative, but not other 3-substituted indoles, have an 
effect on cell viability. I3C treatment caused apoptosis characterized by loss of mitochondria 
membrane potential and caspase activation. I3C alters the expression of proteins involved in 
the control of apoptosis and transcription regulation in EBV-positive Burkitt’s lymphoma 
cell lines. Among those, cMYC, cIAP1/2 and XIAP downmodulation at mRNA and protein 
level precede apoptosis induction, thus suggesting a role in I3C cytotoxicity. We also 
showed that I3C and, more particularly, its condensation dimer 3,3’-diindolylmethane 
(DIM) prolonged survival and reduced tumor burden of mice xenotransplanted with EBV-
positive Burkitt’s lymphoma Daudi cells. 
In summary these results, together with previous reports from clinical trials indicating the 
lack of toxicity in humans of I3C and derivatives, support the use of these compounds as a 
new therapeutic approach for treating patients with endemic (EBV-positive) Burkitt’s 
lymphoma. 
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1. BACKGROUND 
Indole-3-carbinol (I3C) is a glucobrassicine derivative that is found in plants of the 
Cruciferae family, particularly in members of the Brassica genus, such as broccoli, cabbage, 
and cauliflower. I3C is an orally bioactive compound that is formed by the hydrolysis of 
glucosinolate by the plant enzyme myrosinase [1]. Several studies have described the 
activity of I3C and both natural and synthetic derivatives as chemopreventive and anti-tumor 
agents, regulating processes such as inflammation, cell proliferation, and tumor invasion [2-
4]. Indeed, I3C has been shown to inhibit proliferation and induce apoptosis of a variety of 
tumors and cell lines of breast, endometrium, prostate, and colon cancer (reviewed in [2]).  
Several studies have assessed the molecular mechanisms involved in I3C anti-tumor 
activities (reviewed in [2]). It has been shown that I3C and derivatives are potent estrogen 
and androgen receptors antagonists and aryl hydrocarbon receptor agonists. Also, I3C could 
revert multiple drug resistance in K562 erythroleukemic cells by downregulating P-
glycoprotein. I3C and oligomers are potent AKT inhibitors and disrupt AKT-dependent 
survival pathways. Interestingly, Takada and coworkers [5] showed that I3C suppressed 
NFκB activation and prevented TNF-mediated induction of  NFκB-regulated genes 
encoding proteins involved in the control of cell proliferation and apoptosis, including 
cyclin D1, IAP family and  BCL2 family proteins, among others.  
Previous reports have proposed that the biological activity of I3C is associated with its 
capacity of forming oligomers in acidic media, such as the stomach milieu [2,6]. Studies in 
human patients revealed that I3C and derivatives can be efficiently administered orally [7,8]. 
Importantly, concentrations at μM range of I3C-conjugation products could be reached in 
plasma and accumulate in tissues after oral intake of these compounds without any 
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significant side-effect on the health of the patients [7] and mice [9,10].  Most importantly, 
clinical trials assessing the effect of oral administration of I3C and its dimer 3,3’-
diindolylmethane (DIM) have demonstrated their safety in humans [11]. Most interestingly, 
there is clinical evidence of the effectiveness of I3C in promoting regression of 
papillomavirus-dependent precancerous lesions of cervix [12] and larynx [13-15].   
Burkitt’s lymphoma is a highly aggressive form of non-Hodgkin’s B-cell lymphoma that is 
usually found in extranodal sites or presenting as an acute leukemia [16-18]. Burkitt’s 
lymphomas are often classified in three main clinical variants: 1) the endemic variant, which 
constitutes the most common childhood malignancy in equatorial Africa and that is 
associated with Epstein-Barr virus (EBV) infection, a member of the herpesvirus family, 2) 
the sporadic variant, found in other regions of the world and also frequently affecting 
children, and 3) the immunodeficiency-associated variant, common in AIDS patients.  
Available treatment for Burkitt’s lymphoma result in about 80% remission in patients with 
localized disease, although this success is reduced to 50% in children with more widespread 
disease. Furthermore, current treatment involves intensive combination chemotherapy, the 
need for intrathecal treatment, and risk of tumor lysis syndrome, which precludes its use in 
the elderly and limits access to treatment to patients in developing countries [19]. For those 
reasons, it is a necessity to develop new therapies that facilitate access to treatment and 
minimize therapy-associated toxicity.  
In the present study, we have studied whether I3C and other 3-substituted indoles have anti-
tumor activity on Burkitt’s lymphoma. Our results show that only I3C and its derivatives are 
effective in reducing the viability of both latency I and II EBV-positive Burkitt’s 
lymphomas both in vitro and in vivo, while having no effect on EBV-negative BL cell lines. 
Our data indicate that I3C cytotoxic activity involves cMYC and IAP family 
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downmodulation, with subsequent induction of apoptosis. Altogether our results suggest that 
these compounds might provide a new therapeutic approach for treating patients with 
endemic (EBV-positive) Burkitt’s lymphoma.   
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2. MATERIALS AND METHODS 
2.1. Reagents and antibodies. Indole compounds were purchased from Sigma-Aldrich (St. 
Louis, MO). Mass spectrometry analysis of indole-3-carbinol (I3C; 1H-indole-3-methanol) 
and 3,3’-diindolylmethane (DIM) confirmed the purity (> 95% and > 98%, respectively) and 
integrity of these compounds as reported by the supplier. The rest of reagents and antibodies 
are described in supplementary Materials and methods. 
2.2. Cell lines and cell culture. Burkitt’s lymphoma B cell lines BL-2, BL-41, BL-60.2, 
Daudi, DG-75, Mutu-1, Raji, Jijoye, Namalwa, Rael, Akata and Ramos and the 
immortalized EBV-infected lymphoblastoid cell lines JY, Dana, Alewife and IB-4 were 
cultured in RPMI 1640 medium supplemented with 10% inactivated fetal calf serum (FCS; 
Life Technologies, Madrid, Spain), 2 mM L-glutamine, 100 U/ml penicillin and 100 μg/ml 
streptomycin at 37 ºC in a humidified atmosphere containing 5% CO2. Microsatellite 
analyses of cell lines are provided in supplementary table T1. 
2.3. LMP1 expression analysis. Intracellular LMP1 expression was determined using a 
commercial fixation/permeabilization kit (Fitx&Perm; Invitrogen Life Technologies), 
following the manufacturer’s instructions. A detailed protocol is provided in supplementary 
Materials and methods.  
2.4. Viability assays. Cells (106 cells/ml; 100 μl/well) were incubated in 96-well microtiter 
plates and cultured in the presence of the indicated reagents. Viability was determined at 24 
and 48 h by using the kit CellTiter 96© AQUEOUS Assay (Promega Biotech Iberica, Madrid, 
Spain), following the manufacturer’s instructions. The spectrophotometric absorbance of 
each sample was measured at 490 nm using the BioTek Synergy Mx microplate reader 
(BioTek Instruments, Winooski, VT).  
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 2.5. Apoptosis detection. Apoptosis was determined by annexin V/PI staining. Briefly, 
cells (2-5 x 105 cells) were harvested and incubated with FITC-labeled annexin V and 1 
μg/ml PI in binding buffer (5 mM CaCl2, 10 mM Hepes, and 140 mM NaCl). After 15 min 
in the dark, they were analyzed by flow cytometry.  
2.6. Western blot analysis. Western blot was carried out as previously described [20]. A 
detailed description is provided in supplementary Materials and methods. Densitometry was 
performed on scanned images using Quantity One software (Bio-Rad Laboratories), and 
values were normalized for corresponding controls of each experiment.  
2.7. Determination of mitochondrial depolarization. Mitochondrial transmembrane 
potential (ΔΨm) was assessed by staining with TMRM. Cells (106 cells/ml) were 
preincubated with 250 nM TMRM for 20 min and then incubated in the presence of the 
different reagents. At indicated times cells were washed with PBS and analyzed by flow 
cytometry using a FC 500 MPL cytofluorimeter and the CXP software version 2.1 
(Beckman Coulter Inc., Fullerton, CA). An excitation wavelength of 488 nm and 
observation wavelength of 585 nm for red fluorescence were used for analyzing 
mitochondrial depolarization, which is indicated by the number of cells losing red 
fluorescence. The protonophore CCCP (25 µM) was used as a positive control. 
2.8. Quantitative polymerase chain reaction (Q-PCR). Total RNA was extracted from 5 x 
106 BL-60.2 (n = 3) or Ramos (n = 1) cells using TRIZOL reagent and the PureLinkTM RNA 
mini kit (Ambion, Life Technologies). Q-PCR was carried out by the Service of Genomics 
from IIB by means of the Applied Biosystems 7900HT Fast Real-Time PCR System 
(Applied Biosystems, Life Technologies), using a SYBR Green probe. The primers were as 
follows: BIRC3 F: 5’TGAGCATGCAGACACATGC and R: 
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5’TGGATCATCTCCAGATTCCC; MCL1 F: 5’GGTAATAACACCAGTACGGACG and 
R: 5’GATAATCTCCAGCGACTGCC;  MYC F: 5’AGAGAAGCTGGCCTCCTACC and 
R: 5’TCGAGGAGAGCAGAGAATC; XIAP F: 5’GCCAGACTATGCTCACCTAACC and 
R: 5’GCAATTAGGAAAGTGTCGCC. The relative expression of each mRNA was 
calculated as the ΔCt (value obtained by subtracting the Ct number of target sample from 
that of control sample, 18S subunit). The amount of target mRNA relative to 18S mRNA 
was thus expressed as 2-(ΔCt). Values are given as the ratio of the target mRNA to 18S 
mRNA. 
2.9. In vivo animal studies. 8-12 weeks-old NOD/SCID (Non-obese Diabetic/Severe 
Combined Immunodeficiency) male mice were i.p. injected with 107 EBV-positive BL 
Daudi cells. Two weeks after tumor inoculation, mice were administered three times a week 
by oral gavage either with 150 µl ethanol:corn oil (1:9) or 180 mg/Kg I3C or DIM dissolved 
in vehicle (ethanol:corn oil (1:9)). Mice showing symptoms of distress and pain (heavy 
breath, cachexia, lack of reactivity to stimulus) were euthanized. The animal protocols were 
approved by the Institutional Animal Care and Use Committees from the hosting Institution.  
2.10. Data analysis. All experiments were performed at least three times, unless otherwise 
indicated, obtaining similar results. Treated samples and controls were compared using the 
paired Student’s t-test when normally distributed or the paired Wilcoxon’s test when not. 
Survival analysis and correlations were performed using the Kaplan-Meier and the 
Spearman´s or Pearson´s tests, respectively. Differences were regarded as significant when p 
< 0.05.    
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3. RESULTS 
3.1. I3C efficiently reduces the viability of EBV-positive Burkitt’s lymphoma cell lines 
in culture but lacks toxicity against EBV-negative Burkitt’s lymphoma cell lines and 
EBV-infected lymphoblastoid cell lines 
I3C has been reported to induce death of a variety of solid tumors and myeloma cells [2,5] 
and it has been proven effective in preventing papillomavirus-dependent carcinogenesis in 
clinical trials [12-15]. Epstein-Barr virus is a member of the Herpesviridae family that is 
involved in the etiology of Burkitt’s lymphoma and other lymphoid malignancies. To 
determine whether I3C might also be deleterious to EBV-driven tumors, we tested the 
ability of I3C to induce cell death in Burkitt’s lymphoma (BL)-derived cell lines. Thus, we 
analyzed the effect of increasing I3C concentrations on the viability of a collection of EBV-
positive and EBV-negative BL cell lines. As shown in Fig. 1A and supplementary Table T2, 
I3C efficiently reduced cell viability of EBV-positive BL cell lines in a dose-dependent 
manner, while I3C did not significantly affect the viability of EBV-negative BL cell lines 
(Fig. 1B and supplementary Table T2). Indeed these differences in survival between EBV-
positive and EBV-negative BL were significant with I3C concentrations as low as 50 μM 
(24 h, p = 0.047; 48 h, p = 0.022), although the higher statistical significance was reached 
with I3C 200 μM at 48 h (p < 0.0001). Furthermore, the effect of I3C on the viability of 
EBV-positive BL cell lines seemed to be independent of their latency stage. Thus, latency I 
cell lines, such as Akata, Mutu-1, Rael, BL-60.2, Daudi and Namalwa, that are characterized 
by the expression of viral protein EBNA1 but not of LMP1, and latency II BL cell lines, 
such as Jijoye and Raji, which expressed both EBNA1 and LMP1, but lacked EBNA2 
expression (Fig. 1D and E, and data not shown), showed comparable reduction in viability 
in response to increasing I3C concentrations.  
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This result prompted us to determine whether other EBV-carrying cell lines were also 
sensitive to I3C. For that purpose we tested the effect of I3C on the viability of a variety of 
immortalized EBV-infected lymphoblastoid cell lines that constitutively express high levels 
of latency III EBV genes, including EBNA1, EBNA2 (Fig. 1D) and LMP1 (Fig. 1E) and 
data not shown), which are involved in apoptosis protection [21]. These cells would 
recapitulate the virus expression patterns seen in infectious mononucleosis and post-
transplant lymphoproliferative disorders [22].  As shown in Fig. 1C and supplementary 
Table T2, I3C had no effect on the viability of any of the EBV-infected lymphoblastoid cell 
lines tested, thus suggesting that I3C might only be effective in transformed cells expressing 
a restricted EBV expression program such as those characteristic of latency I and II. 
We next studied whether other 3-substituted indoles also have a deleterious effect on the 
viability of the EBV-positive BL cell lines BL-60.2 (latency I) and Raji (latency II) (Figure 
2). In addition, we also tested the effect on cell viability of indoline, and 1H-indole-2-
methanol. Among the indole compounds tested, only I3C and its C6-methylated analog [(6-
methyl-1H-indol-3-yl) methanol] caused a significant reduction in the viability of both BL-
60.2 (Fig. 2A, top panel) and Raji (Fig. 2A, bottom panel). Interestingly, C6-methylated-I3C 
was more potent than I3C in both cell lines, indicating that substitution at the benzene-fused 
ring might enhance the anti-tumor activity of either I3C or its oligomer products.  
3.2. I3C induces caspase activation and mitochondria membrane depolarization 
To determine the mechanism of I3C-induced cell death we tested whether I3C induces 
apoptosis or necrosis by assessing annexin V-FITC/PI double staining using flow cytometry 
analysis. As shown in Fig. 3A, I3C (200 μM) efficiently triggered apoptosis, as evidenced 
by the labeling of dying cells with annexin V (15%) and annexin V/PI (52%) after 15 h of 
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incubation. Consistent with the induction of apoptosis, the pan-caspase inhibitor Z-VAD-
fmk efficiently blocked I3C-dependent cell death.   
The analysis of the apoptosis pathways triggered by I3C in EBV-positive BL cell lines BL-
60.2 and Raji showed the proteolytic activation of apical caspases of both the extrinsic 
(caspase 8) and intrinsic (caspase 9) apoptosis pathways, as well as of executioner caspase 3 
(Fig. 3B). PARP cleavage was also readily observed after I3C-treatment, and I3C-dependent 
PARP cleavage and caspases activation were prevented by incubation of cells with the 
caspase inhibitor Z-VAD-fmk in all EBV-positive BL cell lines tested, including Raji, BL-
60.2 (Fig. 3B) and Daudi (supplementary Fig. S1). In contrast, I3C failed to trigger caspase 
activation and PARP cleavage in EBV-negative BL cell line Ramos and in EBV-infected 
lymphoblastoid cell line Dana, in agreement with the lack of effect of I3C on the viability of 
these cell lines (Fig. 3B).  
Interestingly, we also observed phosphorylation in Ser139 of histone H2A.X in response to 
I3C treatment. Induction of phosphorylated H2A.X (also known as -H2A.X) is an early 
event occurring after DNA damage and is dependent on ATM/ATR [23,24]. However, a 
caspase-dependent induction of -H2A.X has also been described, which is dependent on the 
proteolytic activation of MTS-1 kinase by caspases [25,26]. Our results show that incubation 
of EBV-positive BL cell lines BL-60.2, Raji, and Daudi with I3C caused a dose-dependent 
induction of -H2A.X, which is observed at I3C concentrations as low as 20-50 μM (Fig. 3B 
and supplementary Fig. S1). Moreover, incubation of cells with Z-VAD-fmk completely 
abrogated -H2A.X induction, thus indicating that this event was fully dependent on caspase 
activation. In contrast, I3C failed to induce -H2A.X induction in EBV-negative BL cell line 
Ramos and EBV-infected lymphoblastoid cell line Dana (Fig. 3B), in agreement with our 
results, indicating that I3C does not trigger caspase activation in these cell lines.  
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To further characterize the pro-apoptotic effect of I3C, we next assessed whether this 
compound altered mitochondrial membrane potential (Δψm), which is a critical event 
preceding cytochrome c release and the formation of the apoptosome. Indeed, Δψm 
depolarization was observed in BL-60.2 cells as early as 5 h after incubation with I3C. In 
Raji cells, Δψm depolarization took longer but was evident after 8 h of incubation with I3C 
(Fig. 3C). Consistent with I3C-mediated mitochondrial depolarization, we found very 
limited production of both mitochondrial ROS production (supplementary Materials and 
methods and supplementary Fig. S2A). Also, cytosolic ROS did not accumulate in response 
to I3C in these cell lines and time frame (supplementary Materials and methods and 
supplementary Fig. S2B), thus suggesting that ROS production is not required for I3C-
mediated apoptosis induction in EBV-positive BL cells.    
On other hand, there are several reports supporting a role for I3C in cell cycle arrest [2,27]. 
However, our results using BL-60.2 cells did not show any I3C-dependent alteration of cell 
cycle, and the percentage of cells in G1, S and G2/M were similar, irrespective of the 
presence or absence of I3C in the culture (supplementary Materials and methods and 
supplementary Fig. S3). Moreover, our results also indicate that I3C-induced apoptosis in 
BL-60.2 cells is cell cycle-independent since induction of apoptosis did not correlate with 
any significant alteration of the percentage of cells going through the different phases of the 
cell cycle (supplementary Fig. S3). 
3.3. I3C alters the levels of expression of proteins involved in the control of cell survival 
in EBV-positive BL cell lines 
We next examined the effect of I3C on the expression levels of several proteins known to 
regulate cell survival and apoptosis, including the BCL2 family members BCL2, MCL1, 
BCLXL and BAX, the inhibitors of apoptosis (IAP)-family members cIAP1/2 and XIAP, 
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and the protease-deficient caspase 8 homolog cFLIPL.  For these experiments, EBV-positive 
BL cell lines BL60.2 (Fig. 4A), Raji (Fig. 4B) and Daudi (supplementary Fig. S1), the EBV-
negative BL cell line Ramos (Fig. 4C) and the EBV-infected lymphoblastoid cell lines Dana 
(Fig. 4D) were incubated in the presence of increasing concentrations of I3C (0-200 μM) for 
24 h. As shown in Fig. 4 and supplementary Fig. S1, I3C causes striking downregulation of 
both XIAP and cIAP1/2 in EBV-positive BL cell lines BL-60.2, Daudi, and Raji, while no 
effect on these proteins was observed in EBV-negative BL Ramos cells or in EBV-infected 
lymphoblastoid cell line Dana. This downmodulation was caspase-independent, since it was 
not prevented by the caspase inhibitor Z-VAD-fmk.   
In addition, I3C also caused evident downmodulation of MCL1 in all EBV-positive BL cell 
lines, while slight downmodulation of BCLXL was only observed in Raji cells. No 
significant effect of I3C on the expression levels of BCL2, BAX and β-ACTIN (used as 
loading control) was observed. In contrast, I3C caused cFLIPL expression upregulation in 
both Raji and BL-60.2 cells.     
3.4. Differential effects of I3C on the expression of transcription factors and 
modulators related to Burkitt´s lymphoma etiology 
The defining and most relevant genetic alteration involved in Burkitt´s lymphoma etiology 
is the (8:14) translocation that causes cMYC overexpression. The mechanism by which 
cMYC upregulation contributes to BL cell transformation is related to its effects on cell 
proliferation, genomic instability and deregulated apoptosis (reviewed in [16]). To assess 
whether I3C has any effect on cMYC expression, BL-60.2 (Fig. 5A), Raji (Fig. 5B), Ramos 
(Fig. 5C) and Dana (Fig. 5D), as well as Daudi (supplementary Fig. S1) cell lines were 
incubated in the presence of I3C (0-200 μM) for 24 h. As expected, cMYC was 
overexpressed in BL cell lines, but it was undetectable in EBV-infected lymphoblastoid cell 
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line Dana. Our results showed that cMYC was downregulated by I3C at concentrations as 
low as 20-50 μM in all EBV-positive BL cell lines tested, including BL-60.2, Daudi and 
Raji cells (Fig. 5 and 6, and supplementary Fig. S1). This downmodulation takes place very 
rapidly, being observed before the induction of apoptosis, as shown in Fig. 6A. Consistent 
with this result, cMYC downmodulation was not prevented by Z-VAD-fmk (Fig. 5 and 
supplementary Fig. S1). 
It is worth mentioning that upregulation of cFLIPL expression observed in Raji and BL-60.2 
cells (Fig. 4) is consistent with cMYC inhibition, since this transcription factor is a known 
transcriptional repressor of CFLAR, the gene encoding cFLIPL  [28]. In contrast, I3C did not 
have any effect on cMYC expression in EBV-negative BL Ramos cells, even though this 
cell line also harbors the 8:14 MYC translocation found in Raji and BL-60.2 cells. 
Besides cMYC, other transcription factors such as E2F1 [29], E2F4 [30], TCL1 [31] and 
transcription modulators such as the retinoblastoma-related protein pRb2/p130  [32] have 
been involved in BL etiology. Thus, we also studied the effect of I3C on these transcription 
factors. Expression levels of E2F4 and pRb2/p130 were also reduced by I3C in Raji and BL-
60.2 cells, although their expression levels remained unaltered in Ramos and Dana cells. 
However, E2F4 and pRb2/p130 downmodulation in EBV-positive BL cells was caspase-
dependent as it was partially reverted by Z-VAD-fmk. In contrast, the expression levels of 
mutated p53, E2F1 and TCL1, were not significantly affected by I3C in any of the cell lines 
tested.  
We also assessed the effect of I3C on EBNA1 protein levels. EBNA1 is the only viral 
protein that is expressed in all EBV-positive BL cell lines and primary tumors and has been 
involved in apoptosis protection [33] and transcription reprogramming of infected cells [34]. 
As shown in Fig. 5A, B, and supplementary Fig. S1, I3C causes the reduction of EBNA1 
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expression levels in EBV-positive BL cell lines, particularly in BL-60.2 cells, although this 
reduction was prevented by Z-VAD-fmk, thus implying that it was dependent on the 
activation of caspases. In contrast, EBNA1 expression levels in EBV-infected 
lymphoblastoid cell line Dana remained unaltered by I3C. 
3.5. I3C downmodulates MYC, BIRC3 and XIAP transcription 
To further assess the mechanism involved in protein downmodulation in response to I3C, we 
checked whether it was caused by transcriptional inhibition. We therefore determined the 
expression levels of the mRNAs encoding cIAP2 (BIRC3), XIAP (XIAP), cMYC (MYC) and 
MCL1 (MCL1) by Q-PCR. EBV-positive Burkitt´s lymphoma BL-60.2 cells and EBV-
negative BL Ramos cells were incubated with 100 μM I3C for 15 h, then total RNA was 
extracted, retrotranscribed and subjected to real time PCR using primers specific for the 
genes of interest. As shown in Fig. 7, we observed a significant reduction in the levels of 
mRNA encoding cIAP2, XIAP and cMYC in BL-60.2 cells treated with I3C, while the 
expression levels of these mRNAs were not affected by I3C in Ramos cells. These results 
strongly suggest that transcriptional inhibition is involved in the downmodulation of the 
expression of these proteins in response to I3C in EBV-positive BL cells. In contrast, MCL1 
mRNA levels were not significantly affected by I3C in BL-60.2 and Ramos cells.  
It is worth mentioning that previous report by Takada and coworkers [5] in  myeloma cells 
showed that I3C inhibited NFκB causing downmodulation of different targets involved in 
the control of apoptosis, including cIAP1/2, XIAP, and cFLIPL. However, NFκB1 activity 
has been shown to be suppressed in Burkitt´s lymphoma [35]. Our data have shown that 
incubation of Raji cells with 200 µM I3C at 2h (not shown), 9h and 24 h (supplementary 
Fig. S4A) did not alter the subcellular localization of RELA (p65) and NFκB1 (p50), which 
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are mostly found in cytosol, and that it did not have any effect on p100 processing into p52 
(NFκB2) nor did alter its subcellular localization.  However, we observed downmodulation 
of cMYC, XIAP and cIAP1/2 expression after 9h of incubation with I3C (supplementary 
Fig. S4A), suggesting that NFκB inhibition is not likely involved in I3C-mediated 
downmodulation of these proteins in EBV-positive BL cells. Moreover, as shown in 
supplementary Fig. S4B, immunohistochemical analysis of RELA (p65) expression in EBV-
positive BL Daudi cells xenografted in NOD/SCID mice showed that treatment either with 
vehicle or I3C did not altered RELA (p65) expression levels nor did it affect its subcellular 
localization which was prominently cytosolic in both conditions. These results further 
confirm that I3C do not alter RELA (p65) expression and subcellular localization even in 
long in vivo I3C treatments (see below). Furthermore, downmodulation of cMYC, XIAP and 
cIAP1/2 occurred in the absence of caspase activation, as determined by the absence of 
PARP cleavage. In contrast, EBNA1 expression was not affected by I3C after 9h but its 
expression was dramatically reduced after 24h, coincident with overt apoptosis 
(supplementary Fig. S4A). 
3.6. I3C and its dimer 3,3’-diindolylmethane (DIM) reduce tumor burden and prolong 
survival of xenotransplanted mice 
Next, we investigated whether I3C and its dimer DIM could reduce tumor burden and 
prolong survival of NOD/SCID mice that were i.p. xenotransplanted with EBV-positive BL 
Daudi cells. DIM (Fig. 8A) is an I3C dimer, which is the major product formed by I3C 
condensation in acidic aqueous solutions, similar to the conditions found in the stomach [6]. 
DIM has been proposed to be the physiologically active form of I3C (reviewed in [1]). Mice 
were i.p. inoculated with Daudi cells and were left untreated for 2 weeks to allow tumor 
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implantation. Then, mice were administered 3 times a week by oral gavage with 150 μl 
vehicle (ethanol:corn oil 1:9) with or without either I3C or DIM (180 mg/Kg).  
At the time of death, mice treated with vehicle showed disseminated lymphoma (2.18 ± 0.26 
g; n = 9) (Fig. 8B).  However, although I3C-treated mice also had disseminated lymphoma 
at the time of death, the weight of the tumor (1.3 ± 0.3 g; n = 7) was significantly reduced 
compared to that of vehicle-treated mice (p = 0.02) (Fig. 8B). In addition, as shown in 
Figure 8C, survival time of I3C-treated mice was longer than that of vehicle-treated mice, 
although it did not reach statistical significance (p = 0.2). As shown in Fig. 8D, mice treated 
with DIM (n = 6) survived significantly longer than mice treated with vehicle only (p = 
0.012), and 3 mice in the experiment were alive at day 121 while all mice in the control 
group were dead between days 62-70 (Fig. 8D). Moreover, the weight of the tumor in DIM-
treated mice at the time of death or sacrifice was 0.6 ± 0.2 g (vehicle vs DIM, p = 0.0005) 
(Fig. 8B).  
To further assess the effect of I3C and DIM in vivo, we performed a histochemical analysis 
of tumors isolated from mice treated with vehicle, I3C and DIM. As shown in 
supplementary Fig S5, cMYC expression was prominent in the Daudi tumors isolated from 
vehicle-treated mice. However, cMYC expression was strikingly downmodulated in mice 
treated with I3C, which also evidenced the presence of scattered pyknotic nuclei indicative 
of apoptosis. Most interestingly, tumors from DIM treated mice showed an even larger 
reduction in cMYC expression and abundance of pyknotic nuclei. Altogether, these results 
indicate that, compared to I3C, DIM has a more potent anti-tumor effect in vivo against 
EBV-positive BL Daudi cells.   
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4. DISCUSSION 
In this report we have shown that I3C, a naturally occurring dietary component found in 
broadly consumed vegetables of the Brassica genus, shows potent anti-tumor activity 
against EBV-positive BL cell lines. I3C is derived from glucosinolates produced by plants 
such as broccoli, Brussels sprouts, and cabbage, where it is found at concentrations ranging 
from 0.2-4 mg/g [36]. Previous reports have proposed that the biological activity of I3C is 
associated with its capacity of forming oligomers in acidic media, such as the stomach 
milieu [6]. Its major condensation product is its dimer DIM, which can reach μM 
concentrations in plasma and organs similar to those used in this study. Indeed, the area 
under the curve value for I3C-condensation products after I3C intake (1g) in human plasma 
was 22 µM x h [7], and 160 µM x h in plasma and 1.4 mmoles x h x g-1 in liver of mice after 
oral intake of 7.5 mg of DIM, the major condensation product of I3C [9,10].  
The specificity of the anti-tumor effect of I3C against EBV-positive BL cell lines is 
highlighted by the fact that several other 3-substituted indoles and 1H-indole-2-methanol 
had no significant effect on the viability of EBV-positive BL cell lines. Interestingly, most 
of the inactive 3-substituted indoles tested present moieties that are either bioisosteres of the 
3-hydroxymethylene possessed by I3C or slightly modified. Consequently, these compounds 
should generate similar chemical interactions with the I3C biological targets and should also 
have some anti-tumor activity, but they do not, thus further suggesting that I3C is a pro-drug 
that can be biotransformed into active oligomers. Our results showing the lack of anti-tumor 
activity of the 3-substituted indoles tested and of 1H-indole-2-methanol would be in support 
of this hypothesis since none of these compounds can form oligomers in physiologic 
conditions or in acidic media. In this regard, the I3C dimer DIM has been shown to be the 
major I3C condensation product formed in neutral and acidic aqueous medium and it has 
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been proposed to be the biologically active form of I3C both in vivo and in vitro, since 
conversion of I3C to DIM in cell cultures has also been described [37,38]. However, it is 
worth noting that the low water solubility of DIM (1.4 μM, EPISuiteTM, U.S. Environmental 
Protection Agency) has limited any comparative study of the in vitro anti-tumor activity of 
I3C and DIM on EBV-positive BL cell lines. However, our in vivo studies did indeed 
demonstrate that DIM has a more potent anti-tumor effect in vivo compared to I3C. In this 
regard, NOD/SCID mice xenografted with EBV-positive BL Daudi cells treated with either 
vehicle, I3C or DIM showed that although I3C caused reduction of tumor growth and 
slightly increased survival time compared to vehicle treated mice, DIM treatment caused a 
significantly larger reduction of tumor weight and prolonged survival of the xenografted 
mice.   
Previous results have shown the effectiveness of I3C in clinical trials in patients with 
precancerous lesions of the cervix and laryngeal papillomas, both of which are related to 
infection with human papillomavirus. Our results showing that I3C efficiently induces 
apoptosis of all tested BL cell lines infected with EBV, a member of the herpesvirus family, 
but failed to reduce the viability of any EBV-negative BL analyzed, would suggest that I3C 
might be active against tumors in which virus infection contributes to tumor transformation. 
In this regard, EBV asymptomatically infects over 90% of the world adult population and its 
involvement in the etiology of endemic BL is well established. Although the contribution of 
EBV to tumor transformation is yet to be elucidated, protection from apoptosis seems to be 
implicated [16,39]. Interestingly, the majority of EBV-positive Burkitt´s lymphomas and 
derived cell lines are latency I, which is characterized by the sole expression of EBNA1 and 
non-coding EBER RNAs. However, some EBV-positive BL cell lines in culture and 
lymphomas such as EBV-positive Hodgkin lymphoma and EBV-positive NK/T cell 
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lymphoma, express latency II genes, including LMP1 [22,40]. Indeed, the EBV-positive cell 
lines that we have used in this study are mostly latency I, expressing only EBNA1, but in 
two of them, Jijoye and Raji, expression of LMP1 was also detected, thus implying that 
EBV-positive BL cell lines were sensitive to I3C irrespective of LMP1 expression.  
We have also investigated whether I3C might have an effect on the viability of cells from 
other EBV-dependent pathologies in which a majority of the virus genome is expressed 
(latency III).  For these experiments we used EBV-infected lymphoblastoid cell lines. Our 
results showed that I3C had no effect on the viability of these cells, thus arguing against any 
therapeutic effect of I3C on diseases in which latency III viral proteins are expressed, such 
as post-transplant lymphoproliferative disorders and infection mononucleosis. These results 
also suggest that either the higher levels of EBNA1 that are expressed in latency III cells or, 
most likely, latency III-specific proteins may protect from I3C-induced cytotoxicity. 
The defining oncogene in Burkitt´s lymphoma is MYC. Translocations that juxtapose MYC 
on chromosome 8 with the IgH genes on chromosome 14 or, less frequently, with IgL genes, 
are found in the vast majority of BL cases, whether they are or not associated with EBV. 
Overexpression of cMYC activates both proliferation and apoptosis. In the case of EBV-
positive BL, it has been proposed that EBV promotes cMYC transformation by 
counteracting the pro-apoptotic activities of cMYC [21,33,41]. In addition, it is well 
established that cMYC overexpression represses part of the virus transcription program 
restricting it to latency I, thus implying a tight relation between cMYC upregulation and 
EBV infection in the development of BL [42,43]. Our studies about the effect of I3C on the 
expression of different proteins relevant to BL etiology and on the regulation of cell death 
showed that cMYC was one of the most sensitive targets to I3C treatment. Indeed, 
downmodulation of cMYC expression was readily observed with I3C concentrations as low 
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as 20-50 μM and just 2.5 h after I3C addition in EBV-positive BL BL-60.2, Raji, and Daudi. 
However, no effect on cMYC expression was observed in EBV-negative BL Ramos cell 
line. This is surprising since BL-60.2, Raji, Daudi and Ramos cells harbor the t(8:14) MYC 
translocation, although the IgH/cMYC junctions of these translocations are different and 
might have different regulatory requirements [44]. Interestingly, the observation that 
expression of cFLIPL, the product of CFLAR, a gene transcriptionally repressed by cMYC 
[28], is upregulated by I3C in EBV-positive BL cells is in support of a functional 
implication of cMYC downmodulation in the proapoptotic activity of I3C. Interestingly, 
cFLIPL has been shown to play a dual role in apoptosis by either preventing or promoting 
caspase 8 activation and function [45,46 ,47,48]. In fact, many evidences indicate that 
cFLIPL can associate with and promote caspase 8 activation, thus acting as a bonafide pro-
apoptotic molecule depending on its expression levels and cell context [45,49,50]. 
I3C-mediated downmodulation of cIAP1/2 and XIAP in response to I3C treatment would 
have a direct impact on the ability of EBV-positive BL cells to survive. Our data indicate 
that cIAP1/2 and XIAP expression is strikingly downmodulated by I3C in a process that is 
transcriptionally regulated and caspase-independent. As shown in Fig. 6, downmodulation 
of cMYC and IAP proteins clearly precede caspase activation, as determined by caspase-
dependent H2A.X phosphorylation, which is a highly sensitive marker of caspase activity, 
suggesting that suppressing these proteins is a key requirement for I3C-mediated 
cytotoxicity in EBV-positive BL cells.   
Finally, it is intriguing why the cytotoxic effect of I3C and derivatives and the effect of this 
compound on cMYC and IAP proteins expression are only observed in BL cells with latency 
I/II EBV program and not in EBV-negative BL cells. One explanation would be that I3C is 
interfering with the cellular survival program established by the virus. However, it is 
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possible that EBV-negative BL rely on additional survival factors or enzymes that render 
I3C inactive. Further research on this matter is warranted. 
In conclusion, we show that I3C and derivatives efficiently promote both in vitro and in vivo 
apoptosis of latency I and II EBV-positive BL cell lines, while having no effect on EBV-
negative BL or in EBV-infected LCLs (latency III). The specific pro-apoptotic effect of I3C 
in EBV-positive BL cells correlates with the downmodulation of cMYC expression and of 
IAP family members cIAP1/2 and XIAP at both protein and mRNA levels. The low toxicity 
of I3C and its dimer DIM, already confirmed in clinical trials, supports their use in clinics to 
treat patients with endemic (EBV-positive) Burkitt´s lymphoma.  
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FIGURE LEGENDS 
Figure 1. I3C induces cell death in EBV-positive BL cell lines but not in EBV-negative BL 
cell lines or EBV-infected lymphoblastoid cell lines (LCL). EBV-positive BL (A), EBV-
negative BL (B), and EBV-infected LCL (C) cell lines (106 cells/ml) were cultured in triplicates 
in medium without or with increasing doses of I3C (20-200 μM). 48 h later, the percentage of 
viable cells was determined considering the control value as 100% viability. (D) A total of 12 μg 
of protein were subjected to 8% SDS-PAGE and immunoblotting with specific antibodies 
against the indicated proteins. ERK2 was used as a loading control. LMP1 expression is 
indicated as positive or negative considering the result obtained by flow cytometry. (E) For 
LMP1 expression, 106 cells of each cell line were fixed and permeabilized, and incubated with 
anti-LMP1 1:100 and then with goat anti-mouse F(ab’)2-FITC 1:100. Cells were analyzed by 
flow cytometry. 
 
Figure 2. Effect of different 3-substituted indoles on EBV-positive BL cell lines viability 
(A) BL-60.2 and Raji cells were cultured in triplicates in medium containing vehicle control (< 
0.02% ethanol or DMSO) or with increasing doses of the indicated compounds (20-200 μM). 
After 24 h and 48 h, the percentage of viable cells was determined by a colorimetric assay 
considering the control condition as 100% viability. (B) Structural formula of the chemical 
compounds used in (A). 
 
Figure 3. I3C induces apoptosis in EBV-positive BL cell lines by a caspase-dependent 
mechanism. (A) BL-60.2 cells (106 cells/ml) were cultured in triplicates in medium 
containing vehicle control (0.02% ethanol/DMSO) or with 200 μM I3C.  When indicated, 
cells were preincubated with 100 μM Z-VAD-fmk (ZVAD) for 30 min. After 15 h, the 
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percentage of viable cells was determined by flow cytometry analysis of annexin-V FITC 
and PI. (B) EBV-positive BL BL-60.2 and Raji cells, EBV-negative BL Ramos cells and 
EBV-infected LCL Dana (106 cells/ml) were cultured in medium with vehicle (0.02% 
ethanol/DMSO) or with increasing concentrations of I3C (20-200 μM). When indicated, 
cells were preincubated with 100 μM Z-VAD-fmk (ZVAD) for 30 min. After 24 h of 
incubation cells were lysed and a total of 12 μg of protein were subjected to 8-13% SDS-
PAGE and immunoblotting with specific antibodies against the indicated proteins. p65-
NFκB was used as a loading control. (C) I3C induces mitochondrial depolarization. BL-60.2 
and Raji cells (106 cell/ml) were preincubated with 250 nM TMRM for 30 min and then 
cultured in the presence of vehicle control (< 0.02% ethanol) or 200 μM I3C. At indicated 
times, cells were harvested and analyzed by flow cytometry in the FL-2 channel. Cells 
cultured with 25 μM CCCP were used as a positive control of mitochondria membrane 
depolararization. 
Figure 4. Analysis of the effect of I3C on the expression of different proteins implicated in 
the control of apoptosis. BL-60.2 (A), Raji (B), Ramos (C) or Dana (D) cells (106 cells/ml) 
were cultured in medium containing vehicle control (0.02% ethanol/DMSO) or with increasing 
doses of I3C (20-200 μM). When indicated, cells were preincubated with 100 μM Z-VAD-fmk 
(ZVAD) for 30 min. After 24 h of incubation cells were lysed in Laemmli buffer and sonicated. 
A total of 12 μg of protein from each sample were subjected to 8-10% SDS-PAGE and 
immunoblotting with specific antibodies as indicated. β-ACTIN was used as a loading control. 
Figure 5. Analysis of the effect of I3C on the expression of transcription factors and co-
factors involved in BL etiology. BL-60.2 (A), Raji (B), Ramos (C) or Dana (D) cells (106 
cells/ml) were cultured in medium containing vehicle control (0.02% ethanol/DMSO) or with 
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increasing doses of I3C (20-200 μM). When indicated, cells were preincubated with 100 μM Z-
VAD-fmk (ZVAD) for 30 min. After 24 h of incubation cells were lysed and a total of 12 μg of 
protein from each sample were subjected to 8-13% SDS-PAGE and immunoblotting with 
specific antibodies as indicated. β-ACTIN was used as a loading control. 
Figure 6. Analysis of I3C-dependent expression downmodulation and activation of cMYC 
and pro- and anti-apoptotic proteins. (A) Raji cells (106 cells/ml) were cultured with vehicle 
control (< 0.02% ethanol) or 200 μM I3C for indicated times. Cells were lysed in Laemmli 
buffer and sonicated. In all cases, 12 μg of protein were subjected to 8-13% SDS-PAGE and 
immunoblotting with specific antibodies as indicated. β-ACTIN expression was used as a 
loading control. It is shown the percentage of expression of the different proteins normalized for 
β-ACTIN. (B) Raji, (C) BL-60.2, and (D) Daudi cells (106 cells/ml) were cultured with vehicle 
control (< 0.02% ethanol) or increasing doses of I3C (20-200 μM) for 24 h. Cells were lysed in 
Laemmli buffer and sonicated. In all cases, 12 μg of protein were subjected to 8-13% SDS-
PAGE and immunoblotting with specific antibodies as indicated. β-ACTIN expression was used 
as a loading control. It is shown the percentage of expression of the different proteins 
normalized for β-ACTIN. 
Figure 7.  I3C-mediated protein downmodulation is caused by transcription inhibition.  
BL-60.2 (n = 3) and Ramos (n = 1) cells (106 cells/ml) were cultured with vehicle control (< 
0.02% ethanol) or 100 μM I3C for 15 h. RNA was extracted and gene expression analysis of the 
indicated genes was carried out by Q-PCR. BL-60.2 data show the mean ± standard deviation of 
the relative mRNA expression in cells treated with I3C respective to their levels in non-treated 
cells. Statistical significance was obtained using two tails paired Student´s t-Test.  
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Figure 8. Treatment with I3C or DIM reduces tumor burden and prolongs survival of a 
Burkitt’s lymphoma xenograft model. (A) Structural formula of I3C and DIM. (B) 
Comparison analysis of the tumor weight developed by mice treated with either vehicle, I3C or 
DIM. NOD/SCID mice were injected i.p. with 107 Daudi cells. After two weeks animals were 
treated orally three days in a week with vehicle alone (control) (n = 9), or containing either 180 
mg/Kg of I3C (n = 7) or 180 mg/Kg of DIM (n = 6). Mean ± SEM is shown. Statistical 
significance was assessed by unpaired t Student analysis. (C) Kaplan-Meier survival curves of 
vehicle-treated (n = 8) vs I3C-treated mice (n = 8). (D) Kaplan-Meier survival curves of vehicle-
treated (n = 5) vs DIM-treated mice (n = 7). Differences were significant (p = 0.012). 
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Indole-3-carbinol induces cMYC and IAP-family downmodulation and promotes 
apoptosis of EBV-positive but not EBV-negative Burkitt’s lymphoma cell lines 
Gema Perez-Chacon, Cristobal de los Rios and Juan M. Zapata 
Supplementary Materials and Methods 
Reagents and antibodies 
The pan-caspase inhibitor Z-Val-Ala-DL-Asp-fluoromethylketone (Z-VAD-fmk) was 
from Bachem (Bubendrof, Switzerland) and the stock was dissolved in DMSO. 
Proteasome inhibitor Bortezomib was kindly provided by Millenium Pharmaceuticals 
(Cambridge, MA). Lactacystin, carbonyl cyanide m-chlorophenylhydrazone (CCCP), 
2’,7’-dichlorofluorescein diacetate (H2DCF-DA), cationic fluorophore 
tetramethylrhodamine methyl ester (TMRM) and propidium iodide (PI) were from Sigma-
Aldrich. MitoSoxTM red mitochondrial superoxide indicator was from Life Technologies 
(Grand Island, NY). Antibodies against cMYC (N-262), IκBα (C-21), p65 (C-20), p50 (C-
19), E2F1 (C-20), E2F4 (C-108), p130 (C-20), ERK2 (C-14), EBNA1, and EBNA2 
(Santa Cruz Biotechnology Inc., Santa Cruz, CA), PARP, BCLXL and XIAP (BD 
Biosciences, San Jose, CA),  CASPASE 3, CASPASE 8, CASPASE 9, p53, p100/p52 
NFκB2, TCL1, and γ-H2A.X (Cell Signaling Technologies, Danvers, MA), cIAP1/2, 
(R&D Systems, Abingdon, UK), cMYC (06-340, Millipore, Temecula, CA), and cFLIPL 
and β-ACTIN (Sigma-Aldrich) were used for western blot analysis. LMP1 mAb (Acris 
Antibodies, Herford, Germany), annexin V (BioVision, Milpitas, CA), and goat anti-
mouse-FITC F(ab’)2 (Agilent Technologies, Barcelona, Spain) were used for flow 
cytometry. Antibodies against human BCL2, MCL1 and BAX have been previously 
described (1-3). Anti-rabbit and anti-mouse HRP-conjugated secondary antibodies were 
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from BioRad Laboratories (Madrid, Spain). Anti-rat and anti-goat HRP-conjugated 
secondary antibodies were from Santa Cruz Biotechnologies. 
Western Blot analysis. Cell lysates were prepared in incomplete Laemmli buffer 
(0.125M Tris pH 6.8, 4% SDS and 20% glycerol) supplemented with phosphatase and 
protease inhibitors (cOmplete and PhosSTOP tablets, Roche Diagnostics, Mannheim, 
Germany). Lysates were sonicated and the concentration of total proteins was determined 
by the bicinchoninic acid method (Pierce, Rockford, IL). Proteins were resolved on 8-
13% SDS-PAGE gels and transferred to PVDF membrane. After transfer and blocking 
with 5% non-fat dry milk or 3% BSA in TBS/0.05% Tween-20 at room temperature for 2 
h, membranes were then probed with the indicated antibodies followed by incubation with 
HRP-conjugated secondary antibodies in blocking solution. Specific bands were 
visualized using enhanced chemiluminescence. 
LMP1 expression analysis. Intracellular LMP1 expression was determined using a 
commercial fixation/permeabilization kit (Fitx&Perm; Invitrogen Life Technologies). 
Briefly, 106 cells were fixed with 100 µl Reagent A for 15 min, washed with PBS, and 
then permeabilized with 100 µl Reagent B for 15 min. After washing, cells were 
incubated with 50 µg/ml γ-globulin for 10 min and then with anti-LMP1 1:100 for 20 
min. Cells were washed and incubated with goat anti-mouse F(ab’)2-FITC 1:100 in the 
presence of 50 µg/ml γ-globulin for 20 min. Finally, cells were analyzed by flow 
cytometry using a FC 500 MPL cytofluorimeter and the CXP software version 2.1 
(Beckman Coulter Inc., Fullerton, CA). 
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Determination of reactive oxygen species (ROS). Cells (106 cells/ml) were incubated in 
the presence of the different reagents at indicated times and then stained with 1 μM 
H2DCF-DA (cytosolic ROS) or 5 μM MitoSoxTM (mitochondrial ROS) for 30 min. Cells 
were washed with PBS and analyzed by flow cytometry in the FL-1/FITC or the FL-2/PE 
channel, respectively, as an indicator of ROS production. Serum deprivation was used as 
a positive control. 
Cell cycle analysis. Cells (106 cells/ml) were cultured in the presence or in the absence of 
200 μM I3C. After indicated times, 2 x 106 cells were harvested and centrifugated for 5 
min at 200 g, then cells were resuspended in 1.5 ml of PBS at 4 ºC and 3.5 ml of ice-cold 
100% ethanol were added drop-wise while gentle vortexing. Cells were incubated for 45 
min at 4 ºC and then overnight at -20 ºC. Fixed cells were centrifugated for 10 min at 200 
g, resuspended in 2 ml of PBS and centrifugated for 8 min at 200 g, repeating this process 
twice. Cell pellets were resuspended in 500 µl of PI solution (PBS containing 15 µg/ml of 
PI and 15 µg/ml of RNAse) and incubated for 15 min at room temperature in the dark. 
Finally, cells were analyzed by flow cytometry using the ModFit LT software (Verity 
Software House, Topsham, ME). 
Subcellular fractionation.  Raji cells (107 cells) were resuspended in 150 µl lysis buffer 
(0.3 M sucrose, 100 mM KCl, 10 mM Hepes pH 7.4, 1.5 mM MgCl2, 0.5 mM DTT, 0.3% 
NP-40, and protease inhibitor cocktail) and incubated on ice for 2 min. Cell lysis was 
verified by phase-contrast microscopy, Then, lysates were centrifugated for 5 min at 2000 
g to pellet nuclei, and supernatant (cytoplasm) and pellet (nuclei) were collected. The 
supernatant was centrifugated for 10 min at 4000 g to remove residual nuclei. The nuclear 
pellet was resuspended in lysis buffer and centrifugated for 5 min at 2000 g to remove 
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residual cytosolic components. Then, nuclei were resuspended in 150 µl Laemmli buffer, 
to normalize cytosolic and nuclear fractions for cell equivalents, and sonicated. 
Immunohistochemistry. Tissues and organs from transgenic mice were fixed in 10% formalin, 
embedded in paraffin, and tissue sections (5 µm) were stained with hematoxylin and eosin 
(H&E) and with anti-cMYC polyclonal antibody (Millipore). For mmunohistochemistry, color 
was developed using a diaminobenzidine-based detection method (Vector Laboratories, 
Burlingame, CA), and sections were then counterstained with hematoxylin, dehydrated, and 
mounted in DPX (Fluka). 
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Supplementary Table T1. Microsatellite analysis. Cell lines used in this study were 
subjected to microsatellite analysis for identity confirmation and to rule out possible 
contamination with other cell lines. Burkitt´s lymphoma cell lines Daudi, Jijoye, 
Namalwa, Raji, BL-2, BL-41, DG-75 and Ramos were analyzed using the StemElite 
System from Promega, following the manufacturer’s instructions. Analyses were 
performed in an ABI3130XL genetic analyzer and analyzed using the Gene Mapper 
software (Applied Biosystems, Life Technologies). Microsatellite results were verified 
using published data from DSMZ and ATCC. Of note is that Burkitt´s lymphoma cell 
lines Rael, BL-60.2, Mutu-1 and Akata, and EBV-infected lymphoblastoid cell lines 
Alewife, Dana, JY and IB-4 were not included in these analyses since no microsatellite 
information on these cell lines is found in DSMZ and ATCC databases.   
M Musculus D5S818 D13S317 D7S820 D16S539 VWA TH01 AMEL TPOX CSF Ref. Coincidence
Daudi Negative 8.13 11.12 8.10 10.12 15.17 6.7 X,Y 8.11 12 ATCC 100%
Jijoye Negative 12 12 8.10 10.11 15.19 7.9 X,Y 6.8 10.11 ATCC 100%
Namalwa Negative 12.13 11.12 11 9 14 7,9.3 X 6.11 10.11 ATCC 100%
Raji Negative 10.13 13 10 8.11 16.19 6.7 X,Y 8.13 10.12 ATCC 100%
BL-2 Negative 12 11.12 8.12 12 15.16 6 X,Y 8.11 11.13 ATCC 100%
BL-41 Negative 11.13 8.11 9.11 12 14.18 7,9.3 X,Y 7.8 10.11 ATCC 100%
DG-75 Negative 12 10.11 11.3,12 11.12 17,18,19,20 6.7 X,Y 8.11 10.12 DSMZ 83%
Ramos Negative 7.12 13.14 11 10.13 15.16 7,9.3 X 8.9 10.11 ATCC 100%
 
 
 
Supplementary Table T2  
  
I3C efficiently reduces cell viability in EBV-positive Burkitt´s lymphoma cell lines but it has no effect in EBV-negative Burkitt´s 
lymphoma and EBV-infected lymphoblastoid cell lines viability.  Cells (105) were incubated in the presence of the indicated 
concentrations of I3C and cultured at 37 C in 5% CO2 atmosphere.  Cell viability was determined 24 h and 48 h after I3C addition using 
the CellTiter 96© AQUEOUS Assay (Promega Biotech Iberica, Madrid, Spain), following the manufacturer’s instructions. Data shows 
average +/- SD of three independent experiments in which each condition was analyzed in triplicate.  
   
      Time (h)    24 h    48 h  
 
  I3C (µM)    20  50  100  150  200    20  50  100  150  200  
EBV+ BL   
BL-60.2  94 ± 6 89 ± 7 63 ± 14 43 ± 16 29 ± 10     104 ± 6 89 ± 4 28 ± 6 12 ± 1 12 ± 3 
Jijoye  101 ± 4 100 ± 4 94 ± 4 87 ± 8 75 ± 7    
  
  
  
  
  
  
  
   
  
  
  
  
  
99 ± 2 98 ± 2 90± 6 79 ± 17 53 ± 25  
Raji  98 ± 3 91 ± 9 67 ± 11 53 ± 13 50 ± 11  98 ± 3 77 ± 9 37 ± 9 26 ± 10 20 ± 2 
Mutu-1  96 ± 4 97 ± 6 97 ± 6 93 ± 4 88 ± 4  96 ± 1 94 ± 6 91 ± 8 82 ± 4 62 ± 7 
Daudi   93 ± 2 72 ± 4 42 ± 7 37 ± 8 32 ± 7  96 ± 1 43 ± 8 26 ± 15 22 ± 11 16 ± 8 
Namalwa  103 ± 4 99 ± 5 92 ± 8 86 ± 10 62 ± 17  97 ± 4 92 ± 10 77 ± 17 60 ± 9 31 ± 17  
Akata  97 ± 4 94 ± 7 92 ± 11 88 ± 17 81 ± 26  97 ± 5 88 ± 9 62 ± 27 44 ± 34 26 ± 20  
Rael  92 ± 3 61 ± 6 20 ± 1 19 ± 2 15 ± 4  99 ± 16 44 ± 16 29 ± 1 21 ± 14 16 ± 13  
EBV- BL  
BL-2  99 ± 1 98 ± 1 96 ± 6 95 ± 2 91 ± 6  98 ± 0 98 ± 1 98 ± 1 94 ± 9 75 ± 7 
BL-41  103 ± 4 103 ± 4 103 ± 5 103 ± 4 96 ± 1  100 ± 6 100 ± 3 95 ± 4 89 ± 1 76 ± 5 
DG-75  107 ± 5 106 ± 10 104 ± 7 106 ± 8 105 ± 11  107 ± 8 113 ± 8 112 ± 6 105 ± 21 87 ± 23  
Ramos  102 ± 1 102 ± 1 109 ± 8 110 ± 9 108 ± 6  102 ± 1 104 ± 4 105 ± 6 101 ± 4 92 ± 3 
EBV+ LCL  
Alewife  102 ± 1 103 ± 1 105 ± 1 105 ± 6 103 ± 5  100 ± 1 98 ± 1 99 ± 4 97 ± 4 99 ± 1 
IB-4  98 ± 4 98 ± 1 100 ± 1 103 ± 6 102 ± 7  104 ± 6 109 ± 5 117 ± 2 131 ± 8 145 ± 8  
JY  102 ± 2 105 ± 2 106 ± 3 103 ± 4 100 ± 9  105 ± 4 112 ± 6 119 ± 6 115 ± 1 102 ± 14  
Dana  97 ± 1 97 ± 1 97 ± 1 101 ± 5 102 ± 3  98 ± 1 96 ± 1 96 ± 2 95 ± 3 93 ± 4 
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Supplementary Figure S1. Analysis of the effect of I3C on the expression of cMYC, 
EBNA1 and different proteins implicated in the control of apoptosis in EBV-positive BL 
Daudi cells. Daudi cells (106 cells/ml) were cultured in medium containing vehicle control 
(0.02% ethanol/DMSO) or with increasing doses of I3C (20-200 μM). When indicated, 100 
μM Z-VAD-fmk (ZVAD) was added. After 24 h of incubation cells were lysed in Laemmli 
buffer and sonicated. A total of 12 μg of protein from each sample were subjected to 8-13% 
SDS-PAGE and immunoblotting with specific antibodies as indicated. β-ACTIN was used as 
a loading control. 
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Supplementary Figure S2. I3C does not induce ROS production in EBV-positive 
Burkitt´s lymphoma cell lines. A. I3C does not induce mitochondrial ROS 
production. BL-60.2 and Raji cells (106 cell/ml) were cultured in the presence of vehicle 
control (< 0.02% ethanol) or 200 μM I3C. At indicated times, cells were harvested and 
stained with 5 μM MitoSoxTM for mitochondrial ROS production measuring (mROS) and 
analyzed by flow cytometry. Cells cultured in serum-free medium were used as a positive 
control. B. I3C does not induce cytosolic ROS production. BL-60.2 and Raji cells (106 
cell/ml) were cultured in the presence of vehicle control (< 0.02% ethanol) or 200 μM I3C. 
At indicated times, cells were harvested and stained with 1 μM H2DCF-DA for cytosolic 
ROS production measuring (cROS) and analyzed by flow cytometry. Cells cultured in 
serum-free medium were used as a positive control. 
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Supplementary Figure S3. I3C does not induce any significant cell cycle alteration in 
BL-60.2 EBV-positive Burkitt´s lymphoma cells. BL-60.2 cells were cultured with 
vehicle control (< 0.02% ethanol) o with 200 μM I3C for indicated times. Then, 2 x 106 
cells were harvested and effects of I3C on the cell cycle were determined by flow 
cytometry of PI-stained nuclei as described in supplementary Materials and methods. (A) 
A representative histogram of cell cycle at 8, 15 and 24 h. (B) The bar graph show the 
percentage of cells in each phase of cell cycle (G1, S and G2/M), according to the analysis 
using the ModFit LT software. 
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Supplementary Figure S4. I3C does not alter the subcellular localization or 
processing of NFκB proteins. A. Raji cells were incubated in the presence of vehicle 
(0.02% ethanol) or I3C (200 μM). After 9h and 24 h of incubation, cells were harvested, 
washed with PBS and nuclei and cytoplasm were isolated as described in Materials and 
methods. Then, a total of 15 μg of cytoplasmic protein and the corresponding volume of 
nuclear protein were subjected to 8% SDS-PAGE and immunoblotting with specific 
antibodies as indicated. B. NOD/SCID mice were xenotransplanted with EBV-positive BL 
Daudi cells and treated either with vehicle or I3C as described in Materials and methods. 
Mice were euthanized when the mouse treated with vehicle showed symptoms of terminal 
disease. Figure shows the staining with anti-RELA (p65) ab. Bar: 25 µm. 
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Supplementary Figure S5. Effect of I3C and DIM treatment in cMYC expression in 
Daudi tumors.  NOD/SCID mice were xenotransplanted with EBV+ BL Daudi cells and 
treated either with vehicle (top panels), I3C (central panels) or DIM (bottom panels) as 
described in Materials and methods. All mice were euthanized when the mouse treated 
with vehicle showed symptoms of terminal disease. Figure shows the staining with 
hematoxylin/eosin (left panels) and immunohistochemical staining with anti-cMYC ab 
(right panels). Bar: 100 µm 
